Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women
2001
Goserelin's Role in Early Breast Cancer for Younger Women
Sample size: 8000
publication
Evidence: high
Author Information
Author(s): Jonat W
Primary Institution: Gynaecology and Obstetrics Clinic, University of Kiel
Hypothesis
Is goserelin as effective as chemotherapy for treating early breast cancer in pre- and perimenopausal women?
Conclusion
Goserelin is at least as effective as chemotherapy for hormone receptor-positive early breast cancer in pre- and perimenopausal women.
Supporting Evidence
- Goserelin has been confirmed as effective in a series of studies involving over 8000 patients.
- Goserelin is effective alone or with tamoxifen for hormone receptor-positive tumors.
- Using goserelin can avoid the side effects of cytotoxic chemotherapy.
Takeaway
Goserelin is a medicine that can help women with early breast cancer without the harsh side effects of chemotherapy.
Methodology
The study analyzed results from multiple studies involving over 8000 patients.
Participant Demographics
Pre- and perimenopausal women with early breast cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website